Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Single-Dose, 1-Period, 1-Treatment Pilot Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone Under Fasting Conditions

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Nanotherapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00880841
First received: April 13, 2009
Last updated: May 5, 2009
Last verified: May 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2009
  Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)